197 related articles for article (PubMed ID: 27428433)
21. Human MxB Protein Is a Pan-herpesvirus Restriction Factor.
Schilling M; Bulli L; Weigang S; Graf L; Naumann S; Patzina C; Wagner V; Bauersfeld L; Goujon C; Hengel H; Halenius A; Ruzsics Z; Schaller T; Kochs G
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950411
[TBL] [Abstract][Full Text] [Related]
22. The interferon-inducible MxB protein inhibits HIV-1 infection.
Liu Z; Pan Q; Ding S; Qian J; Xu F; Zhou J; Cen S; Guo F; Liang C
Cell Host Microbe; 2013 Oct; 14(4):398-410. PubMed ID: 24055605
[TBL] [Abstract][Full Text] [Related]
23. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection.
Goujon C; Moncorgé O; Bauby H; Doyle T; Ward CC; Schaller T; Hué S; Barclay WS; Schulz R; Malim MH
Nature; 2013 Oct; 502(7472):559-62. PubMed ID: 24048477
[TBL] [Abstract][Full Text] [Related]
24. Structural insight into HIV-1 restriction by MxB.
Fribourgh JL; Nguyen HC; Matreyek KA; Alvarez FJD; Summers BJ; Dewdney TG; Aiken C; Zhang P; Engelman A; Xiong Y
Cell Host Microbe; 2014 Nov; 16(5):627-638. PubMed ID: 25312384
[TBL] [Abstract][Full Text] [Related]
25. Host and viral determinants of Mx2 antiretroviral activity.
Busnadiego I; Kane M; Rihn SJ; Preugschas HF; Hughes J; Blanco-Melo D; Strouvelle VP; Zang TM; Willett BJ; Boutell C; Bieniasz PD; Wilson SJ
J Virol; 2014 Jul; 88(14):7738-52. PubMed ID: 24760893
[TBL] [Abstract][Full Text] [Related]
26. Host and viral determinants for MxB restriction of HIV-1 infection.
Matreyek KA; Wang W; Serrao E; Singh PK; Levin HL; Engelman A
Retrovirology; 2014 Oct; 11():90. PubMed ID: 25348155
[TBL] [Abstract][Full Text] [Related]
27. MxB sensitivity of HIV-1 is determined by a highly variable and dynamic capsid surface.
Miles RJ; Kerridge C; Hilditch L; Monit C; Jacques DA; Towers GJ
Elife; 2020 Jun; 9():. PubMed ID: 32553106
[TBL] [Abstract][Full Text] [Related]
28. Oligomerization Requirements for MX2-Mediated Suppression of HIV-1 Infection.
Dicks MD; Goujon C; Pollpeter D; Betancor G; Apolonia L; Bergeron JR; Malim MH
J Virol; 2016 Jan; 90(1):22-32. PubMed ID: 26446602
[TBL] [Abstract][Full Text] [Related]
29. MxB Is Not Responsible for the Blocking of HIV-1 Infection Observed in Alpha Interferon-Treated Cells.
Opp S; Vieira DA; Schulte B; Chanda SK; Diaz-Griffero F
J Virol; 2015 Dec; 90(6):3056-64. PubMed ID: 26719253
[TBL] [Abstract][Full Text] [Related]
30. Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms.
Gallay PA; Ptak RG; Bobardt MD; Dumont JM; Vuagniaux G; Rosenwirth B
Viruses; 2013 Mar; 5(3):981-97. PubMed ID: 23524389
[TBL] [Abstract][Full Text] [Related]
31. Role of MxB in Alpha Interferon-Mediated Inhibition of HIV-1 Infection.
Xu B; Pan Q; Liang C
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925663
[TBL] [Abstract][Full Text] [Related]
32. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 capsid variability: viral exploitation and evasion of capsid-binding molecules.
Saito A; Yamashita M
Retrovirology; 2021 Oct; 18(1):32. PubMed ID: 34702294
[TBL] [Abstract][Full Text] [Related]
34. Dynamins are forever: MxB inhibits HIV-1.
Haller O
Cell Host Microbe; 2013 Oct; 14(4):371-3. PubMed ID: 24139395
[TBL] [Abstract][Full Text] [Related]
35. MXB inhibits murine cytomegalovirus.
Jaguva Vasudevan AA; Bähr A; Grothmann R; Singer A; Häussinger D; Zimmermann A; Münk C
Virology; 2018 Sep; 522():158-167. PubMed ID: 30032029
[TBL] [Abstract][Full Text] [Related]
36. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).
Adamson CS; Ablan SD; Boeras I; Goila-Gaur R; Soheilian F; Nagashima K; Li F; Salzwedel K; Sakalian M; Wild CT; Freed EO
J Virol; 2006 Nov; 80(22):10957-71. PubMed ID: 16956950
[TBL] [Abstract][Full Text] [Related]
37. Virus specificity and nucleoporin requirements for MX2 activity are affected by GTPase function and capsid-CypA interactions.
Layish B; Goli R; Flick H; Huang SW; Zhang RZ; Kvaratskhelia M; Kane M
PLoS Pathog; 2024 Mar; 20(3):e1011830. PubMed ID: 38512975
[TBL] [Abstract][Full Text] [Related]
38. The 4th and 112th Residues of Viral Capsid Cooperatively Modulate Capsid-CPSF6 Interactions of HIV-1.
Saito A; Sultana T; Ode H; Nohata K; Samune Y; Nakayama EE; Iwatani Y; Shioda T
AIDS Res Hum Retroviruses; 2020 Jun; 36(6):513-521. PubMed ID: 31941344
[TBL] [Abstract][Full Text] [Related]
39. Fitness variations and their impact on the evolution of antiretroviral drug resistance.
Menéndez-Arias L; Martínez MA; Quiñones-Mateu ME; Martinez-Picado J
Curr Drug Targets Infect Disord; 2003 Dec; 3(4):355-71. PubMed ID: 14754435
[TBL] [Abstract][Full Text] [Related]
40. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
